Proteomic instability is causally related to human diseases. In guarding proteome stability, the heat shock factor 1 (HSF1)-mediated proteotoxic stress response plays a pivotal role. Contrasting with its beneficial role of enhancing cell survival, recent findings have revealed a compelling prooncogenic role for HSF1. However, the mechanisms underlying the persistent activation and function of HSF1 within malignancy remain poorly understood. Emerging evidence reveals that oncogenic signaling mobilizes HSF1 and that cancer cells rely on HSF1 to avert proteomic instability and repress tumor-suppressive amyloidogenesis. In aggregate, these new developments suggest that cancer cells endure chronic proteotoxic stress and that proteomic instability is intrinsically associated with malignant state, a characteristic that could be exploited to combat cancer.
Recent evidence is beginning to unravel the molecular mechanisms of HSF1 activation and function in regulating proteostasis in cancer. It is conceivable that the hostile tumor microenvironment, often acidic and hypoxic [26, 27] , is disruptive to proteostasis in cancer and stress-provoking. In addition, proteotoxic stress could arise cell-autonomously due to cell-intrinsic alterations. For example, protein biosynthesis is markedly enhanced in cancer cells due to hyperactivation of mTORC1 [28, 29] , a key regulator of translation [30, 31] . Genomic instability of cancer cells also exacerbates proteostasis imbalance. Aneuploidy can increase protein dosage, subsequently exaggerating the proteomic burden [32, 33] . Moreover, oxidative damage of proteins is augmented due to elevated levels of reactive oxygen species (ROS) in cancer cells [34, 35] . Also, numerous genetic mutations cause protein conformational changes that often lead to decreased protein stability [36] .
In this review, we summarize the recent exciting findings in proteomic instability and underscore the critical role of HSF1 and its mediated PSR in preserving proteostasis in cancer. Moreover, we highlight cancer fragile proteostasis as a potential therapeutic target as well as a novel biomarker.
Regulation of HSF1 activity through phosphorylation
The activation of HSF1 upon challenge by proteotoxic stressors is reliant on its phosphorylation ( Figure 1 ). Several phosphorylation events have been reported to promote HSF1 activation, including Ser230 phosphorylation by calcium/calmodulin-dependent protein kinase II (CaMKII) [37] , Ser320 phosphorylation by protein kinase A (PKA) [38] , Thr142 phosphorylation by casein kinase 2 (CK2) [39] , and Ser419 phosphorylation by polo-like kinase 1 (PLK1) [40] . Furthermore, phosphorylation of Ser326 on HSF1 was identified as a modification that is critical to stress-induced HSF1 activation [41] . Originally this modification was found to be mediated by mTOR [42] ; however, a new study indicates that the RAS/MAPK signaling pathway also regulates HSF1 activation through Ser326 phosphorylation [43] (Figure 2 ). Moreover, some HSF1-phosphorylating events negatively impact its transcriptional activity such as Ser121 phosphorylation, which has been linked to metabolic sensors, Ser303, Ser307, and Ser363 phosphorylation [44] [45] [46] .
Activation of HSF1 by oncogenic RAS signaling
The canonical RAS/MAPK signaling pathway governs a plethora of cellular processes including proliferation, differentiation, transcription and translation, and cell survival [47, 48] , and anomalies of this signaling pathway are causally related to a number of human pathological conditions, collectively named RASopathies [49] . Notably, it has been estimated that approximately 30% of all human cancers possess activating somatic mutations in components of this signaling cascade, including RAS, RAF, and MEK genes [50] . Germline mutations of this signaling pathway also underlie several hereditary diseases, including Neurofibromatosis type I (NF1) [51] , Costello syndrome (CS) [52] , Noonan syndrome (NS) [53] , and Leopard syndrome (LS) [54] .
In a recent study, MEK blockade markedly impaired HSF1 Ser326 phosphorylation induced by heat stress, while ERK blockade heightened this phosphorylation [43] . Since ERK has long been regarded as the ultimate effector of the RAS/MAPK signaling cascade [47, 48] , it would be expected that ERK would mediate HSF1 Ser326 phosphorylation. Instead, MEK, the immediate upstream kinase of ERK, physically interacts with and phosphorylates HSF1 at Ser326, both in vivo and in vitro [43] . Furthermore, under heat stress ERK, MEK, and HSF1 assemble into a ternary protein complex, wherein ERK suppresses HSF1 Ser326 phosphorylation through inhibitory phosphorylation of MEK at Thr292 and Thr386 [43] (Figure 2 ). Congruent with its role as a negative regulator of the RAS oncoprotein, loss of the tumor suppressor NF1 constitutively mobilizes HSF1 through activation of MEK [22] . This molecular model reconciles the opposing effects of MEK and ERK on HSF1 activation. The finding that HSF1, in parallel to ERK, is another physiological substrate for MEK is significant in that it has long been thought that ERK was the only substrate for MEK; this finding thus reveals a previously unappreciated complexity of RAS/MAPK signaling. Further, this finding not only highlights a new biological function of RAS/MAPK signaling in regulating the PSR, but also shifts the canonical paradigm of the RAS/MAPK signaling cascade. That is, MEK acts as the central nexus of this signaling cascade, conveying RAS activity to both ERK-and HSF1-mediated pathways simultaneously ( Figure 2 ). While the ERK-and HSF1-mediated pathways are biologically distinct, they are intimately interconnected. ERK, in a negative feedback mechanism, finely attunes MEK-mediated HSF1 activation. These complex regulatory configurations, while ensuring a tight coordination between ERK-and HSF1-mediated pathways, also provide a means to heighten HSF1 activation through ERK inhibition. Given the widespread aberrant alterations in the RAS/RAF/MEK signaling cascade in human malignancies, these new findings reveal that constitutive activation of HSF1 and its mediated PSR is deeply rooted within oncogenic process.
Suppression of HSF1 by metabolic-stress signaling
A recent study reveals that metabolic stressors, including nutrient deprivation and metformin, suppress transcriptional activation of HSF1 in large part through AMP-activated protein kinase (AMPK) [55] (Figure 2 ). AMPK, acting as a key metabolic sensor, closely gauges intracellular AMP/ATP or ADP/ATP ratios [56] . Upon activation under a low cellular energy state, AMPK phosphorylates numerous effectors that control diverse biological processes, including lipogenesis, gluconeogenesis, autophagy, glycolysis, fatty acid oxidation, and protein synthesis [57] . This systemic cellular reaction is collectively referred to as the metabolic stress response (MSR). Through enhancement of ATP production and reduction of ATP consumption, the AMPK-mediated MSR plays a pivotal role in antagonizing metabolic stress and reinstating cellular energy homeostasis [56, 57] . Of note, liver kinase B1 (LKB1/STK11), an immediate upstream kinase of AMPK [58] , is a known tumor suppressor. Germline loss-of-function mutations of LKB1 have been causally linked to Peutz-Jeghers syndrome (PJS) in humans, a cancer-predisposition disorder that manifests hamartomatous polyps in the gastrointestinal tract and mucocutaneous pigmentation [59] .
Upon activation by metabolic stress, AMPK physically interacts with and phosphorylates HSF1 at Ser121 [55] (Figure 2 ). This phosphorylation impairs HSF1 activation, in part, through impedance of HSF1 nuclear translocation [55] . Congruently, glucose deprivation Dai and metformin treatment, both of which provoke metabolic stress and activate AMPK, impair the HSF1-mediated PSR and, in turn, render cells susceptible to heat stress [55] . Importantly, both glucose deprivation and metformin treatment also suppress constitutive HSF1 activation within human cancer cells, depleting cellular chaperoning capacity and subsequently destabilizing the cancer proteome [55] . The identification of HSF1 as a new physiological substrate for AMPK highlights a previously unrecognized relationship between the metabolic and proteotoxic stress responses. In addition to revealing a new mechanism of action underlying the emergent anti-neoplastic effects of metformin, these findings also suggest that activation of HSF1 and suppression of proteotoxic stress may be an important outcome of a cancer cell's reliance on glucose, a phenomenon known as "the Warburg effect".
Following metabolic stress, activated AMPK also suppresses mTORC1 through phosphorylation of RAPTOR [60] . Thus, metabolic stress could also inactivate HSF1 through mTORC1 inhibition, given the reported HSF1 regulation by mTORC1 [42] .
HSF1: a powerful multifaceted facilitator of oncogenesis
In line with its constitutive activation in cancer, amassing evidence has demonstrated that HSF1 potently facilitates oncogenesis. The first proof came from two independent in vivo studies using genetically engineered mouse models. In these experiments, genetic deletion of Hsf1 in mice impaired lymphomagenesis due to Trp53 deficiency [61] , chemical-induced skin carcinogenesis [21] , as well as the multiple instances of tumorigenesis initiated by a "hot-spot" Trp53 mutation [21] . Subsequently, it was shown that Hsf1 deficiency suppresses the development of hepatocellular carcinomas (HCC) induced by pro-carcinogen diethylnitrosamine (DEN) [62] , delays the onset and lung metastasis of mammary tumors in MMTV-HER2/Neu transgenic mice [63, 64] , and impairs carcinogenesis associated with loss of Nf1 [22] .
The pro-oncogenic effects of HSF1 have been further demonstrated in xenograft mouse models. In vivo, HSF1 depletion by RNA interference suppresses growth of human mammary epithelial cells overexpressing HER2 [65] , impairs growth, invasion, and metastasis of HCC cells [66, 67] , and antagonizes growth, invasion, and metastasis of human melanoma cells [68, 69] . Conversely, enhanced HSF1 expression promotes in vivo growth, invasion, and metastasis of melanoma cells [43, 70, 71] . In aggregate, these findings pinpoint HSF1 as a potent pro-oncogenic factor functioning in diverse malignancies.
In addition to its critical role in tumor initiation, emerging evidence strongly suggests that cancer cells become reliant on HSF1 to maintain their malignant phenotypes. Lentiviral shRNA-mediated HSF1 depletion markedly impairs the growth and survival of a collection of human cancer cell lines that are derived from diverse tissue origins and harbor a variety of genetic abnormalities [21] . Independent studies further show that HSF1 depletion or inhibition impairs proliferation of human melanoma cells and HCC cells [43, 68, 69] , induces apoptosis in multiple myeloma cells [72] , and compromises viabilities of malignant peripheral nerve sheath tumor (MPNST) cells [22] , pancreatobiliary cancer cells [73] , and oral squamous cell carcinoma cells (OSCC) [74] .
In sharp contrast, HSF1 depletion barely affects non-transformed cells [21, 73] . In accordance with this result, Hsf1-deficient primary cells and mice remain viable under normal growth conditions [17, 18, 21] . The dependence of malignant cells on HSF1, at least in part, reflects their intrinsic state of chronic stress, an exemplification of the "nononcogene addiction" phenomenon of cancer [75] . Importantly, the addiction to HSF1 imparts an inherent vulnerability of cancer that could be exploited for effective anti-cancer therapies.
HSF1 guards the cancer proteome and suppresses amyloidogenesis
It has been widely recognized that HSP genes are the classic transcriptional targets of HSF1. As molecular chaperones, HSPs maintain the functional conformations and stability of an immense number of cellular proteins, many of which are key oncoproteins. Just a few examples from an ever-increasing list of HSP's client proteins include ERBB2/HER2, c-MET, CYCLIN D1, CDK4, BRAF, and AKT [76, 77] . It is noteworthy that the stabilities of mutant driver oncoproteins generated de novo in cancer, including BCR-ABL, EML4-ALK, and mutant TP53, are particularly reliant on HSPs [76, 78] . In line with its role in stabilizing the cancer proteome, HSF1 depletion diminishes oncoproteins in cancer cells, including EGFR, mutant TP53, KSR1, AKT, and BRAF [22, 68, 79] . Of particular interest, HSF1 depletion also destabilizes ribosomal subunit proteins, including RPL13 and RPL17 [43] . This finding uncovers a previously unrecognized impact of HSF1 on ribosome machinery and reveals an intimate link between cellular chaperoning and translational capacity. Thus, HSF1 promotes oncogenesis not only through enhancement of general protein synthesis but also through stabilization of oncoproteins.
Beyond shortening the half-lives of proteins, HSF1 depletion elicits global protein aggregation as evidenced by increased levels of ubiquitinated proteins that become resistant to detergent extraction [43, 55] . Even more strikingly, amyloids, protein aggregates that are enriched for β sheet structures and are causally associated with several neurodegenerative disorders in humans, emerge in HSF1-deficient cancer cells [43] . Congruent with the critical role of MEK in activating HSF1, pharmacological inhibition of MEK, similarly, induces protein aggregation and amyloidogenesis in cancer cells [43] . Interestingly, under basal conditions in cancer cells, amyloids appear to be readily cleared by proteasomes, as combinatorial proteasome inhibition markedly enhances amyloid formation induced by MEK blockade [43] . Of great importance, malignant cells are particularly susceptible to amyloidogenesis, as the same combinatorial inhibition fails to induce amyloids in primary non-transformed cells and tissues [43] . This unique vulnerability of cancerous cells to proteomic perturbations is in accordance with their intrinsic elevated levels of proteotoxic stress.
Amyloidogenesis is tumor-suppressive as impairment of amyloidogenesis, by either amyloid-binding dyes or a neutralizing antibody, markedly antagonizes the inhibition of growth and survival of cancer cells imposed by combined MEK and proteasome inhibition [43] . Moreover, blockade of amyloid induction through in vivo administration of the popular amyloid stain Congo red not only accelerates melanoma growth, but also mitigates the tumor-suppressive effects of combinatorial MEK and proteasome inhibition [43] .
These findings en masse set forth a paradigm wherein HSF1 critically guards cancer proteome homeostasis, through enhancement of protein synthesis, stabilization of oncoproteins, and suppression of tumor-suppressive protein aggregation and amyloidogenesis. Thereby, HSF1 enables robust oncogenesis (Figure 3 ).
Stress adaptation of cancer enabled by HSF1
The transcriptional action of HSF1 has broader implications than previously expected, extending far beyond those simply engaging in protein folding. It is now recognized that under heat stress and in cancer cells, HSF1 governs the expression of both HSP genes and numerous non-HSP genes [80] . However, HSF1-mediated transcriptional responses are distinct between cancer cells and cell exposed to heat stress, resulting in discrete genomebinding patterns of HSF1 [23] , likely because the stresses endured by cancer cells differ both in type and intensity from those of the classic heat shock response. Indeed, Chromatin Immunoprecipitation Sequencing (ChIP-seq) experiments in malignant cells revealed that HSF1 regulates the expression of genes that are implicated in a diversity of biological processes, ranging from protein translation (e.g. EIF4A2 and RPL22), to cell cycle progression (e.g. CDC6, KNTC1, and POLA2), to DNA repair and chromatin remodeling (e.g. MLH1 and CBX3), to energy metabolism (e.g. FASN and PGK1), and to mRNA processing (e.g. HNRNPA3 and RBM23) [23] . These new findings suggest that through these direct transcriptional regulations, HSF1 is capable of reshaping cellular physiology at the system level by impacting a wide array of cellular pathways. Thus, in addition to guarding the cancer proteome, HSF1 fosters prolific adaptation to chronic proteotoxic stress withstood by cancer cells (Figure 3 ).
Discrete pro-oncogenic functions of HSF1
Beyond its systemic impacts, numerous studies have also revealed discrete functions of HSF1 that promote oncogenesis. In response to oncogenic signals, HSF1 enhances cell growth and survival. Compared to their wild-type counterparts, Hsf1−/− mouse embryonic fibroblasts (MEFs) are refractory to marked proliferation stimulated by oncogenic RAS and platelet-derived growth factor B (PDGF-B), but exhibit heightened cell death upon expression of c-MYC and SV40 large T antigen [21] . In addition, HSF1 suppresses cellular senescence triggered by the HER2/NEU oncogene through induction of HSPs [65] .
HSF1 also augments key oncogenic signaling. Interestingly, while RAS signaling directly activates HSF1 via MEK, this activation, in turn, enhances oncogenic RAS signaling through HSP90-mediated KSR1 stabilization [22] , thus constituting a feed-forward loop. KSR1 is a key scaffold protein that is required to assemble RAF-MEK-ERK signaling complexes [81] .
Furthermore, HSF1 co-opts cellular metabolism to facilitate malignant transformation. HSF1 has been shown to maintain mTORC1 activity in non-transformed cells [21] . It is widely recognized that mTORC1 plays a critical role in cancer by promoting protein translation and suppressing autophagy [28, 29] . Interestingly, compared to their wild-type counterparts, Hsf1−/− MEFs not only display impaired mTORC1 signaling but also are more sensitive to cell cycle arrest induced by the specific mTOR inhibitor rapamycin [21] . Congruent with impaired mTORC1 activity, Hsf1−/− MEFs are 20% smaller in cell size [21] . Although the molecular mechanisms through which HSF1 regulates mTORC1 have not been fully elucidated, this effect of HSF1 is, at least in part, mediated through HSP90, which is required for appropriate mTORC1 assembly [82] . In addition to protein synthesis, HSF1 enhances cellular uptake of glucose, an essential fuel for rampant cancer cell growth [83] , in non-transformed cells [21] . HSF1 achieves this, at least in part, via suppressing expression of thioredoxin-interacting protein (TXNIP) [84] , a potent suppressor of glucose uptake through regulation of GLUT1 [85] . Intriguingly, HSF1 has also been reported to stimulate lipid synthesis through suppression of insulin and AMPK signaling in the normal liver [62] . Given that elevated lipogenesis is widespread in human cancers and critical to membrane synthesis necessary for rapid cancer cell proliferation [86] , this lipogenic effect of HSF1 is proposed to promote development of hepatocellular carcinomas [62] .
Moreover, HSF1 is important to tumor progression. HSF1 has been reported to enhance cell migration and epithelial-mesenchymal transition (EMT) [63, 64, 87] . In Hsf1+/+ mouse mammary epithelial cells that express the HER2/NEU oncogene, TGFβ stimulation induces higher levels of ERK activity and EMT, indicated by reduced expression of the epithelial marker E-Cadherin and increased expression of mesenchymal markers including SLUG and Vimentin [64] . This pro-migratory effect of HSF1 is congruent with its role in promoting tumor invasion and metastasis [64, 66, 70] . In addition, HSF1 is able to sustain angiogenesis in HER2-driven mouse mammary tumors through translational regulation of hypoxiainducible factor 1 (HIF-1) expression [63] , and support anchorage-independent growth of human multiple myeloma cells through induction of HSPs [72] .
Collectively, these findings reinforce the notion that HSF1 adeptly orchestrates an extensive network of cellular functions to facilitate robust oncogenesis systemically.
Targeting fragile proteostasis in cancer: therapeutic strategies and biomarker potential
In light of its multifaceted roles in oncogenesis, it is not surprising that HSF1 is being considered as an attractive therapeutic target. Thus far, several small molecules, including quercetin [88] , KNK437 [89] , triptolide [90] , KRIBB11 [91] , and rocaglates [92] have been reported to suppress the transcriptional activity of HSF1, although the specificity of these inhibitors towards HSF1 remains to be more clearly defined. Alternatively, HSF1-targeting RNAi has been shown to be effective in suppressing its transcriptional activity, at least in vitro [21, 22, 68, 69] . Recently, a RNA aptamer that potently blocks DNA binding of HSF1 has also been developed [93] .
In addition to targeting HSF1 itself, it is feasible to suppress HSF1 activity through modulation of signaling pathways that play critical roles in regulating HSF1 activation. For example, AMPK activators or MEK inhibitors are capable of incapacitating HSF1, albeit in an indirect manner [43, 55] . This promiscuity in action may prove to be advantageous with regard to eradicating malignancy, as these agents impact a wide range of pathways beyond HSF1 and thereby elicit broader and more potent therapeutic effects. While targeting HSF1 or other factors alone could suffice to destabilize the cancer proteome to some extent, it is likely that combinatorial blockade of the proteasome will exhibit profound synergistic effects [43] , and this combination may have additional merits in averting development of resistance to individual inhibitors.
Beyond being an attractive therapeutic target, HSF1 may also serve as a biomarker for cancer prognosis, a notion supported by several recent studies. A study surveying a large cohort of over 1,800 breast cancer patients reveals that in normal mammary epithelial cells HSF1 expression remains low and mainly cytoplasmic; in contrast, HSF1 expression is predominantly nuclear in the majority of malignant tissues, indicative of its activation [94] . Indeed, high levels of nuclear HSF1 proteins correlate significantly with poor prognosis among ER + [94] , HER2 + and triple-negative breast cancer patients [23] . Elevated nuclear HSF1 expression has also been observed in cervical cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, and meningioma [23] . In addition, nuclear HSF1 expression is associated with tumor size in OSCC [95] , and with metastasis and poor survival in endometrial cancer [96] . Further characterization of HSF1 activation in cancer was performed using high-throughput ChIP-seq technologies that profiled targeted genes of HSF1 in a broad range of human cancer cell lines and specimens [23] . The results yielded an "HSF1-cancer signature", encompassing a collection of 456 HSF1-bound genes that displayed a remarkable correlation with shortened survival in patients afflicted with breast, lung, and colon cancer [23] . In aggregate, these findings strongly suggest HSF1 and its mediated stress response is a valuable prognostic marker for a wide array of human cancers. The increased HSF1 expression and activation is, likely, reflective of exacerbated intrinsic stress that inevitably arises from malignant progression.
Concluding remarks
It has become increasingly apparent that cancer cells are constantly confronted by proteotoxic stress from intrinsic and extrinsic factors. The HSF1-mediated stress response, in turn, remains persistently mobilized inside cancer cells and is wholly integrated into their malignant state, thereby containing proteotoxic stress and managing to preserve delicate proteostasis. However, this fragile homeostatic state, owing to chronic intrinsic stress, is particularly vulnerable to perturbations. Consequently, protein destabilization, aggregation, and, ultimately, amyloidogenesis, ensue. Biologically, this proteomic chaos is tumorsuppressive, a phenomenon that could be harnessed to conquer malignancy.
In spite of these exciting new developments, many key questions remain outstanding (Box 3). Whereas phosphorylation plays a crucial role in modulating HSF1 activation, recent studies have implicated other posttranslational modifications, such as acetylation and sumoylation, in this process [97, 98] . It would be interesting to know whether these modifications contribute to HSF1 activation in cancer cells and whether targeting these modifications could also suppress HSF1. Furthermore, to date all of the functions of HSF1 have been exclusively ascribed to its widely recognized transcriptional mechanism; nevertheless, it remains unknown whether HSF1 could, in fact, act independently of gene regulation. Albeit readily induced in cancer cells, the precise identity of these cancerassociated amyloids remains mysterious. The answer to this question is of great importance for a full comprehension of the amyloidogenic phenomenon of cancer. Moreover, in contrast to the apparent cell-autonomous effects of HSF1 on oncogenesis, its non-cell-autonomous effects remain poorly understood. An interesting recent study reports that stromal HSF1 activation promotes malignancy through secretion of transforming growth factor β (TGFβ) and stromal-derived factor 1 (SDF1) [99] . Nonetheless, further investigations are needed to fully delineate how HSF1 influences malignancy through the tumor microenvironment.
OUTSTANDING QUESTIONS
• Do acetylation and sumoylation impact constitutive activation of HSF1 within cancer cells? If yes, can we target these posttranslational modifications to suppress HSF1 in cancer?
• Does HSF1 have transcription-independent functions? If yes, are these noncanonical modes of action critical to oncogenesis?
• What are the identities of cancer-associated amyloidogenic proteins? How do their normal functions influence oncogenesis?
• Does HSF1 co-opt tumor microenvironments to support malignancy?
Whereas genomic instability is widely recognized as a hallmark of cancer, proteomic instability of cancer has drawn little attention. Now evidence is just beginning to shed light on this emerging horizon in mechanisms of cancer, elucidation of which will not only greatly expand our knowledge of cancer biology but will also unlock new avenues to designing novel anti-neoplastic therapies.
Glossary
Amyloidogenesis the process of forming amyloids. Amyloids are protein aggregates that are enriched for highly ordered β-sheet structures and are frequently associated with human neurodegenerative diseases. 
Biological stress

Malignant transformation
the process during which a normal or pre-cancerous cell undergoes drastic biological changes to become a cancerous cell.
Proteome the complete collection of proteins expressed by a cell, tissue, or organism.
Proteostasis
First, new polypeptides are produced by ribosomes; subsequently, these nascent polypeptides fold into appropriate three-dimensional conformations with the assistance of heatshock proteins; and lastly, misfolded or aggregated proteins and proteins reaching the end of their normal lifespan are recognized as wastes and promptly removed from cells via the ubiquitin-proteasomal pathway or the autophagy-lysosomal pathway.
Xenograft mouse model immunocompromised mice that carry transplanted cells or tissues derived from another species, such as human.
TRENDS
• The heat shock factor 1 (HSF1)-mediated proteotoxic stress response (PSR) is an evolutionarily conserved powerful transcriptional program that guards the cellular proteome against the dangers of misfolding and aggregation.
• Cancerous cells suffer chronic proteoteoxic stress from without and within.
• The HSF1-mediated PSR is constitutively mobilized within cancerous cells.
• HSF1 plays a pivotal role in preserving proteomic stability of cancer, thereby enabling robust malignant transformation.
• Disrupting fragile proteostasis in cancer provokes proteomic chaos and tumorsuppressive amyloidogenesis, representing a novel anti-neoplastic therapeutic strategy.
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